Neumora Therapeutics said its Phase 3 trials for navacaprant in major depressive disorder failed to achieve statistical significance on primary and key secondary endpoints, prompting the company to discontinue the program and lay off about 35% of staff. The Koastal-2 and Koastal-3 studies missed on week-6 MADRS score change versus placebo. Neumora noted an unusual pattern in Koastal-3, where patients did better on placebo than navacaprant, and it reiterated that the asset is being discontinued. The company plans to record one-time costs of roughly $2 million from the reorganization and extend its cash runway into the third quarter of 2027. Neumora’s pipeline emphasis after navacaprant includes earlier-stage and other late-readout opportunities across Alzheimer’s disease agitation, schizophrenia, and cardiometabolic disease, but the decision marks a further contraction after its earlier late-stage MDD setback.